Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Quinolone resistance protein NorA is a proton-coupled multidrug efflux transporter found in *Staphylococcus aureus* and belongs to the major facilitator superfamily (MFS)[5][7][8]. NorA actively exports a wide range of antibiotics and toxic compounds out of bacterial cells using a proton gradient, most notably conferring resistance to fluoroquinolones such as norfloxacin and ciprofloxacin[1][4][8]. Overexpression of NorA in S. aureus leads to multidrug resistance phenotypes, and its action is a key barrier to the successful treatment of MRSA infections[3][8]. NorA has become a target for developing efflux pump inhibitors, which could synergize with existing antibiotics to combat resistance[5][8]. The NorA family is defined by structural motifs conserved among MFS transporters, including essential acidic residues (Glu222 and Asp307) that mediate proton coupling and substrate recognition[8].
Drug/H+ antiporter: NorA pumps out antimicrobials and other substrates in exchange for protons, lowering the intracellular concentration of drugs and conferring resistance[1][6][8].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Quinolone resistance protein NorA (NorA).